One hundred and thirty-eight patients with AML underwent ABMT with monoclonal antibody plus complement-purged marrow between August 1984 and March 1997. One hundred and ten patients were in CR (CR1: 23; CR2/3: 87) and 28 were in first relapse (R1) at ABMT. Preparative regimens included busulfan (16 mg/kg) and CY (120 mg/kg) (n ‫؍‬ 93), CY (120 mg/kg over 2 days) with TBI (1200 cGy) (n ‫؍‬ 35), and busulfan (16 mg/kg) plus etoposide (60 mg/kg) (n ‫؍‬ 10). CR1 patients treated with CY/TBI (n ‫؍‬ 7) had 3-and 5-year disease-free survival (DFS) rates of 71% and 57%. CR1 patients treated with BU/CY (n ‫؍‬ 12), had 3-and 5-year DFS rates of 45%. Three and 5-year DFS for CR2/3 patients treated with CY/TBI (n ‫؍‬ 26) was 23%. Three-and 5-year DFS for patients in CR2/3 treated with BU/CY (n ‫؍‬ 55) was 31 and 28%. Threeand 5-year DFS for patients in R1 treated with BU/CY (n ‫؍‬ 26) was 37%. In multivariate analysis, increased age was associated with greater risk of death and relapse. For CR2/3 patients, the length of CR1 was a significant predictor of DFS. ABMT performed in CR or R1 results in excellent 5-year DFS and OS. The contribution of purging may require a randomized trial comparing purged vs unpurged stem cell infusions. Bone Marrow Transplantation (2000) 25, 823-829. Keywords: monoclonal antibodies; acute myeloid leukemia The treatment of AML in children and adults has steadily improved over the past two decades.
free survival of 20-30% at 5 years. The results in these more advanced patients are worse due to a higher relapse rate and to higher treatment-related toxicity.
A major limitation of allogeneic BMT is that it can be applied to only a minority of patients with AML. Only about 40% of patients with AML have histocompatibility antigen (HLA)-matched donors, and most patients over 55 years are considered too old to tolerate this procedure. Studies using allogeneic BMT with matched unrelated donors have demonstrated that advanced disease, older age and higher degrees of HLA disparity are associated with a poor outcome due to excessive morbidity and mortality of GVHD. 4 Therefore, other treatment strategies are necessary for the majority of patients with AML.
ABMT is a promising therapy for the treatment of AML with several advantages over allogeneic BMT: the lack of a bone marrow donor does not preclude treatment, it can be used in patients as old as 65 years and there is no problem with GVHD. There has been concern that the relapse rate with ABMT will be higher than that seen with allogeneic BMT, due to the potential reinfusion of marrow contaminated with clonogenic leukemia cells and the absence of a graft-versus-leukemia effect. However, numerous studies have shown that ABMT can result in outcomes that compare very favorably to those of allogeneic BMT. [5] [6] [7] [8] [9] [10] [11] [12] To increase the efficacy of this treatment, methods of purging autologous marrow using moAb or cytotoxic drugs have been evaluated. [13] [14] [15] [16] [17] [18] We have been using cytotoxic moAb originally created by one of us (EDB) and that react specifically with myeloid cells and recognize antigens expressed on AML blast cells. 19, 20 Of these moAb, PM-81 (anti-CD15) and AML-2-23 (anti-CD14) are the most reactive, binding with leukemia cells from greater than 95% of AML patients. 19, 20 These moAb are cytotoxic to cells bearing the respective cell surface antigens in the presence of complement (CЈ), and thus can lyse leukemia cells from almost all patients with AML, including their progenitor cells. 21 In addition, PM-81 and AML-2-23 do not recognize antigens on multilineage progenitor cells necessary for successful engraftment of bone marrow. 21 From 1 August 1984 until 10 February 1997, 140 purged autologous transplants were performed on 138 patients who were in CR or first relapse (R1) at the time of transplant. Sixty of these patients were described previously. 17 We now report on the long-term results of these phase II studies.
Patients and methods

Patients
Patients less than 65 years of age with a Karnofsky performance status of 80-100% and an expected survival time of greater than 2 months were eligible for this protocol.
At the time of bone marrow harvest, remission was required to be documented by bone marrow aspirate and biopsy. Patients underwent harvest in either first, second or third CR. Transplants were performed in either CR1, CR2, CR3, or first relapse. All patients had a left ventricular ejection fraction у50%, a DLCO of у60% or an FEV у75% predicted as well as adequate renal and liver function as determined by a serum creatinine р2 times normal, and a bilirubin, SGOT (AST), and alkaline phosphatase р3 times normal, respectively. Leukemia blast cells obtained at diagnosis or at relapse, when available, were required to express the antigens reactive with PM-81 and/or AML-2-23 on Ͼ20% of cells. The study was approved by the Institutional Review Board of the respective institutions and a signed informed consent was obtained from each patient prior to study entry.
One hundred and thirty-eight AML patients (with two patients undergoing retransplantation) ranging in age from 2 to 57 and who were in CR or R1 were transplanted between August 1984, and 10 February 1997 (Table 1) . All but 11 patients had de novo AML at the time of initial diagnosis. Eleven patients had a myelodysplastic syndrome (MDS) before the diagnosis of AML. Twenty patients were treated on CALGB protocols 8882 or 8781. Four patients were transplanted at the Scripps Clinic (La Jolla, CA), 59 patients at the Dartmouth-Hitchcock Medical Center The median time between the current remission or relapse and ABMT (n = 137) was 53 days (range 3-420 days). The median time between the current remission or relapse and ABMT for patients in CR1 was 138 days (24-421 days). The median time between the current remission or relapse and ABMT for patients in CR2 was 64 days (3-391 days). The median time between the current remission or relapse and ABMT for patients in CR3 was 36 days (24-83 days). The median time between the current remission or relapse and ABMT for patients transplanted in R1 was 15 days (4-374 days). Sixty-eight patients were harvested in CR1, 64 in CR2, and seven in CR3. One marrow harvest was performed in a patient with an extramedullary relapse (breast chloroma, marrow was normal).
Marrow harvesting and purging
Bone marrow was harvested from the posterior and anterior iliac crests under general anesthesia and passed through a series of filters. 21 Efforts were made to harvest 6 ϫ 10 8 cells/kg from each patient. A mean of 5.37 ϫ 10 8 cells/kg were actually harvested. Bone marrow mononuclear cells were prepared first by buffy coat concentration by apheresis of the marrow. The buffy coat preparation was further treated in some cases on a Ficoll-Hypaque gradient centrifugation on the Haemonetics automated cell processor to obtain a mononuclear cell preparation to be treated with moAb ϩ CЈ. A mean of 1.4 ϫ 10 8 cells/kg were treated; from these, there was a mean recovery of 47%. An average of 6.59 ϫ 10 7 cells/kg was used for the transplant. Saturating amounts of purified moAb were preincubated with these cells as previously described. 22, 23 To ensure saturation of all antigenic sites, the amount of each moAb used was 10 U per 10 6 cells. Treatment on the Haemonetics cell processor was performed for 1 h with continuous exposure to fresh CЈ and simultaneous removal of spent CЈ, while centrifuging at room temperature. 22 The moAb treatment was performed in the presence of the enzyme deoxyribonuclease (10 U/ml) to decrease cell clumping. This treatment was performed on the Haemonetics cell processor for patients treated after May 1987 at the Dartmouth-Hitchcock Medical Center, Bowman Gray Medical Center, and at the University of Pittsburgh. Before that date at the DHMC, Scripps Clinic, Children's Hospital and Health Center (San Diego), and the Medical Center of Delaware, the marrow cells were treated in plastic or Teflon vessels (Savillex, Minnitonka, MN, USA) by gentle shaking. For these treatments, two separate incubations with moAb and CЈ were performed as previously described. 23 As of March 1996, the AML-2-23 moAb was eliminated from the purging regimen based on in vitro experiments demonstrating that AML-2-23 did not add to the cytotoxicity mediated by PM-81 alone.
Cells were then washed and resuspended in a mixture of medium 199 containing 10% dimethyl sulfoxide (Tera Pharmaceuticals, Buena Park, CA, USA) and 5% irradiated autologous plasma, frozen at 1°C/min in a controlled-rate freezer and stored in the vapor phase of liquid nitrogen.
Preparative regimens
Thirty-five patients were treated with the following preparative regimen: cyclophosphamide (CY) (60 mg/kg i.v. for 2 days) (days Ϫ5 to Ϫ3) and fractionated total body irradiation (TBI) (200 cGy twice daily for 3 days, total dose of 1200 cGy, dose rate = 5-10 cGy/min) (days Ϫ2 to 0). In 1988, the preparative regimen was changed from CY/TBI to busulfan (BU)/CY2. Ninety-three patients were treated with BU (4 mg/kg/day orally for days Ϫ8 to Ϫ5) and CY2 (60 mg/kg/day intravenously for 2 days) (days Ϫ4 and Ϫ3). One patient in CR2 was treated with BU (4 mg/kg/day orally for 4 days (days Ϫ9 to Ϫ6) and CY (50 mg/kg/day intravenously for 4 days) (days Ϫ5 to Ϫ2). Ten patients (Stanford) were conditioned with BU (4 mg/kg/day orally days Ϫ7 to Ϫ4) and VP-16 (60 mg/kg day Ϫ3).
Statistical methods
Two patient sets were included in this analysis: The first was the total set of 138 patients and the second was the set of 55 patients who underwent ABMT in CR2/3 and received BU/CY as their conditioning regimen. For both analyses, the last transplant represented was performed on 10 February 1997 and the last follow-up contact was 25 September 1997.
We estimated rates of relapse, OS, and DFS following ABMT (and 95% confidence intervals) using the productlimit or Kaplan-Meier method. 25 In addition, proportional hazards regression (Cox regression, 'relative risk' regression) was used to investigate the association of factors of interest with OS and DFS in these patients. This method assumes that although the survival rates may differ between groups of patients, the probability of death or relapse at a given time maintains a constant ratio throughout follow-up. For the factors examined in this analysis, the assumption appears to be satisfied. The factors listed in Table 2 were allowed to enter the OS and DFS models in a 'forward stepwise' fashion (ie factors were evaluated first individually to see whether they contributed substantially to predicting outcome). The most significant univariate factor was then 'forced into' the model, other factors being allowed to enter if they contributed significantly given the presence of the first. Additional factors were allowed to enter the models with interactions as appropriate. Some factors were transformed before analysis using logarithms to make their distributions more symmetric. . A median number of 4.10 ϫ 10 7 cells/kg body weight (range 2.38-59.6 ϫ 10 7 ) were infused into each R1 patient. Median observed recovery times for neutrophils to 500 cells/l was 33 days. Median times to reach platelet counts of greater than 20 000 and greater than 50 000/l independent of platelet transfusions were 51 and 79 days, respectively. CD34 ϩ cell analysis was available from a subset of 18 patients transplanted at the University of Pittsburgh. There was no significant association between CD34 ϩ cells/kg body weight and relapse or OS (P = 0.17 and 0.71, respectively). There was a significant association (P = 0.036) between CD34 ϩ cells/kg and neutrophil recovery to 500/l as well as platelet recovery to Ͼ20 000 platelets/kg (P = 0.047).
Disease-free and overall survival
The DFS from transplant of all patients as of 25 September 1997 are shown in Figures 1-3 by status at transplant (CR1, CR2/3, and R1). CR1: For patients in CR1 treated with CY/TBI (n = 7) 3-and 5-year DFS rates were 71% and 57% (95% CI: 38-100% and 20-94%) (Tables 3 and 4) . For CR1 patients treated with BU/CY (n = 12) 3-and 5-year DFS rates were both 45% (95% CI: 16-75%). Overall survival at 3 and 5 years for the patients treated with CY/TBI was 71% and 57% (95% CI: 38-100% and 28-94%). OS for patients treated with BU/CY at 3 and 5 years was 46% (95% CI: 16-75%).
CR2/3: Three-and 5-year DFS for patients in CR2/3 treated with CY/TBI (n = 26) were both 23% (95% CI: 7-40%) (Tables 3 and 4) . Three-and 5-year DFS for patients in CR2/3 treated with BU/CY (n = 55) was 31% and 28%, respectively (95% CI: 17-44% and 14-41%). OS for patients treated with CY/TBI at 3 and 5 years was 27% (CI: 10-44%). OS for the patients treated with BU/CY at 3 and 5 years was 38% and 30% (CI: 24-52% and 16-45%).
R1: Three-and 5-year DFS for patients in R1 treated with BU/CY (n = 26) were both 37% (Tables 3 and 4) . OS for the patients treated in R1 with BU/CY at 3 and 5 years was 38% (95% CI: 18%-58%).
Eleven CR1 patients survive disease-free at a median follow-up time of 49 months (range 3-126 months). Twentyseven patients transplanted in CR2/3 survive disease-free at a median time of 55 months (range 1-149 months). Ten patients transplanted in R1 survive disease-free at a median time of 47 months (range 5-96 months). For 48 of 115 CR2/3 and R1 patients, the duration of the post-ABMT remission exceeded the duration of CR1 or CR2.
Relapse
The actuarial relapse rates for different patient groups were calculated using the Kaplan-Meier method. For all patients (n = 138) the relapse rates (RR) were 58% and 61% at 3 and 5 years. For patients in CR1, the RR were 50% and 55% at 3 and 5 years. For patients in CR2/3 the rates were 62% and 65% at 3 and 5 years. For patients in R1 the rates were 56% and 56% at both 3 and 5 years.
Examined by regimen the results were as follows: CR1: CY/TBI, 29% and 43%, at 3 and 5 years; BU/CY: 55% and 55% at 3 and 5 years. CR2/3: CY/TBI: 56% and 56% at 3 and 5 years; BU/CY: 62% and 65% at 3 and 5 years. Patients in R1 treated with the BU/CY regimen: 54% and 54% at 3 and 5 years.
Median time to relapse for patients who relapsed (n = 65) was 5.7 months. Median time to death or relapse (n = 92) was 4.5 months.
Multivariate analysis
Overall survival
All Patients (n = 138): When the factors in Table 2 were evaluated in univariate fashion, age and age у30 were the only variables significantly related to OS (P = 0.047 and 0.025, respectively). As expected, higher age is associated with increased risk of death. When age у30 was 'forced into' the proportional hazards model (ie in a 'multivariate' analysis), no additional factors were found to be significant.
CR2/3 patients conditioned with BU/CY (n = 55):
Among these patients, the strongest single predictor of OS was time in CR1 (P = 0.002). Longer CR1 duration was associated 827 with decreased risk of death. In addition, male patients had a higher risk of death (P = 0.045). When CR1 duration was included in a proportional hazards model, BMI (P = 0.047), gender (P = 0.035), FAB 1 or 2 (P = 0.022) and an extra chromosome 8 (P = 0.048) were all associated with risk of death. The directions of these associations depended on the CR1 duration (ie each factor showed an interaction with CR1). Females with CR1 duration longer than 6 months showed a decreased risk of death compared to males. However, the reverse association was true for females with shorter CR1 duration times. FAB 1 or 2 was a risk factor for death among patients with CR1 duration longer than 6 months. However, FAB 1 or 2 patients with shorter CR1 duration had a decreased risk of death. Patients with high BMI and CR1 duration between 6 and 9 months had a decreased risk of death. Such patients with shorter and longer CR1 duration times were at increased risk. Finally, there was apparently an effect of CR1 time on the risk of death due to an extra chromosome 8. However, because of model fitting problems, it was not possible to describe the interaction between those factors.
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Disease-free survival
All patients: Patient age and age у30 were the only variables significantly related to DFS (P = 0.026 and 0.015, respectively). As was observed in proportional analysis of OS, higher age was associated with increased risk of death or relapse. When age у30 was 'forced into' the proportional hazards model, no additional factors were found to be significant.
CR2/3 patients conditioned with BU/CY:
The only univariate predictor of DFS was time in CR1 (P = 0.003). Longer CR1 duration was associated with decreased risk of death or relapse. When CR1 duration was forced into the model predicting DFS, several additional factors were significantly associated with that outcome: FAB class 1 or 2 (P = 0.045), MDS or secondary AML (P = 0.017), and PM-81 sensitivity (P = 0.025). MDS or secondary AML was strongly associated with increased risk of death or relapse. There were interactions between the other two factors and CR1 duration, although the relationship between PM-81 sensitivity and DFS was obscured by model-fitting problems. Patients with FAB class 1 or 2 and CR1 durations less than 6 months had a lower risk of death or relapse than did patients in the other FAB classes. In contrast, FAB class 1 or 2 patients with longer CR1 durations had a lower risk of death or relapse.
Time to relapse
All patients: In the univariate analysis, conditioning regimen (P = 0.04), age at ABMT (P = 0.03), extramedullary disease (P = 0.02), Ϫ7,7q karyotype (P = 0.04), normal karyotype (P = 0.01), and karyotype-based prognosis (P = 0.01) were associated with time to relapse. Specifi-cally, the Bu/CY and Bu/VP16 regimens had slightly stronger associations with relapse than did the Cy/TBI regimen. Increased age, extramedullary disease, Ϫ7,7q and normal karyotypes were all positively associated with relapse. In particular, a 'normal' karyotype was a worse prognostic factor than either 'good' or 'indeterminate' karyotype. Those karyotypic factors considered 'poor' for prognosis were apparently no worse than a normal karyotype.
In the proportional hazards model resulting from the forward stepwise selection process, several factors were jointly significant in predicting time to relapse: age at ABMT (P = 0.001), extramedullary disease (P = 0.013), karyotype (normal, Ϫ7,7q, or other abnormality; P = 0.001), and history of MDS (P = 0.019). Increasing age was associated with shorter relapse times, although the association was stronger among patients with extramedullary disease. Extramedullary disease was associated with shorter relapse times, with the effect more pronounced among younger patients than among older patients. Patients with a history of MDS tended to have shorter relapse times than did those without such a history. Finally, patients with a Ϫ7,7q karyotype were more likely to relapse than were patients with a normal karyotype. However, patients with other chromosomal abnormalities were less likely to relapse than were patients with a normal karyotype.
Bu/Cy patients transplanted in CR2/3:
When potential risk factors were tested individually for association with time to relapse in this patient group, time in CR1 was the strongest individual predictor (P = 0.002). Patients in CR1 longer than 208 days had longer times to relapse than did patients with shorter CR1 durations. In addition, patients with normal karyotypes were at greater risk for relapse than were patients with karyotypic abnormalities (P = 0.037).
Duration in CR1 (P Ͻ 0.001), karyotype prognosis (P = 0.002), and number of cells transplanted (P = 0.004) were jointly predictive of relapse in the 'multivariate' analysis. As in the univariate analysis, patients in CR1 longer than 208 days had longer times to relapse than did patients with shorter CR1 durations. A higher number of cells transplanted was associated with a shorter relapse time. As with the total patient group, a 'normal' karyotype was a worse prognostic factor than either 'good' or 'indeterminate' karyotype. However, karyotypic factors considered 'poor' for prognosis carried a stronger association with relapse than did a normal karyotype.
Discussion
Bone marrow transplantation offers the potential for complete elimination of occult leukemia cells after initial remission induction, and BMT is probably the only curative treatment for patients with AML after R1. 4 Allogeneic BMT is established as a potentially curative therapy for patients in first remission, but the majority of patients with AML cannot undergo this therapy due to lack of an HLAmatched donor and/or advanced age. 4 This report and others [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] show that ABMT is a viable alternative. Since reinfused marrow may be contaminated with residual malignant cells after ABMT, we have used ex vivo purging to eliminate residual neoplastic cells from the graft. Long-term survival for AML patients after ABMT using various methods for removing occult leukemia cells has been reported. [12] [13] [14] [15] [16] [17] [18] The benefit of mafosfamide purging for patients transplanted in first CR within 6 months of attaining CR has been reported. 16 Chao et al 9 published phase II trial results showing that patients who received purged bone marrow (4-hydroperoxycyclophosphamide (4-HC) and/or etoposide) had an actuarial DFS of 57% compared with a DFS of 32% in patients who received unpurged bone marrow. Yeager et al 13 have reported favorable results similar to allogeneic BMT with 4-HC marrow purging in patients with AML who underwent ABMT.
Miller et al 26 recently demonstrated that 4-HC purged ABMT, reported to the Autologous Bone Marrow Transplantation Registry (ABMTR), had significantly better outcomes than unpurged ABMT in both CR1 and CR2/3.
Brenner et al, 27 using the neomycin-resistant gene as a marker for AML relapse, demonstrated that autologous marrow harvested from leukemia patients in remission may harbor malignant cells capable of contributing to relapse. Thus, effective marrow purging may be essential for improving the outcome of ABMT for AML.
MoAb-based techniques using anti-myeloid moAb have been used to purge AML marrow. This report updates our greater than 10 year multi-institutional clinical data of ABMT in AML with moAb and C-mediated purging. As with allogeneic BMT, the results are dependent on remission status. Five-year DFS for patients transplanted in R1 and CR2/3 who were conditioned with BU/CY2 were 37% and 28%, respectively. These results compare favorably with those of allogeneic BMT. 4, 28 Significant prognostic factors operating in our study were length of first CR (for patients transplanted in R1 or CR2/3), and gender. Interestingly, patients with secondary AML, or extramedullary disease did not fare worse. Nor did cytogenetics of AML cells at diagnosis affect outcome (although some of the patient subgroups were small). These results are surprising since prior CNS disease and cytogenetic abnormalities have been associated with worse outcomes in previous studies. [29] [30] [31] We have conducted a phase II clinical trial of monoclonal antibody purging of bone marrow in patients with AML in remission at the time of harvest and in remission or relapse at the time of transplant. The overriding question raised by the favorable outcomes reported for purged autologous bone marrow transplants is that of how much the purging contributed to the outcomes. This is stimulated by the occasional reports that unpurged marrow transplants have been associated with results often comparable to purged transplants. However, recent evidence has been reported supporting the notion that purging is probably effective in reducing late relapses in AML. 26 Thus, a randomized trial comparing purged to unpurged stem cell transplants in patients with AML in remission may help resolve this issue.
